Tango Therapeutics Q3 2025 net income $15.9M; vopimetostat mPFS 7.2 mo in pancreatic; cash runway into 2028

Tango Therapeutics, Inc.

2025-Q3 EPS reported -$0.57 vs consensus -$0.05 ▼ miss (-959.5%)

Net income $15.9M ($0.14 basic EPS) vs net loss $29.2M in Q3 2024; nine-month net loss $62.8M.
Collaboration revenue $53.8M (Q3 2024: $11.6M) as Gilead collaboration truncated; all deferred revenue recognized.
Vopimetostat in 2L MTAP-del pancreatic cancer showed median PFS 7.2 months; 49% ORR and mPFS 9.1 mo in histology-selective cohort.
October 2025 financing raised $225M gross ($212M net); cash, equivalents and marketables $152.8M as of Sept 30, extending runway into 2028.
TNG456 granted Orphan Drug Designation for malignant glioma; pivotal pancreatic study for vopimetostat anticipated to start 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.